Correspondence 0001171843-23-001133 from Medicenna Therapeutics Corp. (MDNAF) (CIK 0001807983) (MDNAF)
Medicenna Therapeutics Corp. (MDNAF) (CIK 0001807983)
Date: Feb. 23, 2023 · CIK: 0001807983 · Accession: 0001171843-23-001133
AI Filing Summary & Sentiment
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Daniel Crawford Registration Statement on Form F-3 Filed February 17, 2023 File No. 333- 269868 Acceleration Request
Dear Mr. Crawford:
With respect to the above-referenced Registration Statement on Form F-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Medicenna Therapeutics Corp. (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to February 27, 2023, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call John Rudy and Keunjung Cho of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
Very truly yours,
MEDICENNA THERAPEUTICS CORP.
Show Raw Text
CORRESP
1
filename1.htm
MEDICENNA THERAPEUTICS CORP.
2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2
Canada
February 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
RE:
Medicenna Therapeutics Corp.
Registration Statement on Form F-3
Filed February 17, 2023
File No. 333- 269868
Acceleration Request
Dear Mr. Crawford:
With respect to the above-referenced
Registration Statement on Form F-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under
the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Medicenna Therapeutics Corp. (the “Company”),
that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to February 27, 2023, at 4:00
p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff
in meeting the timetable described above is very much appreciated.
Please call John Rudy and
Keunjung Cho of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions
regarding the Registration Statement.
Very truly yours,
MEDICENNA THERAPEUTICS CORP.
/s/ Elizabeth Williams
Elizabeth Williams
Chief Financial Officer
cc:
Elizabeth Williams, Medicenna Therapeutics Corp.
John Rudy, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Keunjung Cho, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.